Kamada (NASDAQ:KMDA) Share Price Passes Below 200 Day Moving Average of $5.64

Kamada Ltd. (NASDAQ:KMDA) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.64 and traded as low as $4.95. Kamada shares last traded at $5.00, with a volume of 1,101 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on KMDA shares. StockNews.com started coverage on shares of Kamada in a research note on Thursday. They issued a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, May 9th.

Kamada Stock Performance

The stock has a market cap of $287.40 million, a P/E ratio of 21.74 and a beta of 1.06. The stock’s fifty day simple moving average is $5.27 and its 200-day simple moving average is $5.64.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The business had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. Kamada had a net margin of 8.33% and a return on equity of 5.50%. As a group, equities research analysts forecast that Kamada Ltd. will post 0.26 earnings per share for the current year.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares during the period. Aristides Capital LLC lifted its stake in Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 16,635 shares during the last quarter. Calton & Associates Inc. bought a new position in Kamada in the 4th quarter valued at approximately $111,000. Y.D. More Investments Ltd lifted its stake in Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 15,000 shares during the last quarter. Finally, EWA LLC bought a new position in Kamada in the 4th quarter valued at approximately $68,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.